Spain Diabetes Devices Market: Market Size & Forecast 2026

Spain represents one of Western Europe's larger diabetes device markets, with estimated 2025 revenues near $931 million across monitoring, insulin delivery, and emerging digital management solutions. The broader Spanish diabetes ecosystem, including pharmaceuticals, reaches approximately $1.26 billion, though device-specific figures remain independently tracked. No official national statistical agency publishes granular market-size data for this segment, so valuations rely on commercial industry analysis.

• •Market valued at approximately $931 million in 2025
• •Combined diabetes drugs and devices market reaches $1.26 billion
• •Official government statistical agencies do not publish granular device-market figures

An aging population and climbing obesity rates are expanding Spain's diabetic and prediabetic populations, directly increasing demand for monitoring and insulin delivery devices. Government encouragement and reimbursement coverage through the national health system have lowered patient cost barriers, accelerating uptake of advanced devices such as CGMs. The digital diabetes management segment is also expanding rapidly as connected health solutions gain clinical acceptance.

• •Aging demographic and rising obesity rates fuel incidence of diabetes
• •Public reimbursement policies improve patient access to advanced devices
• •Prediabetes segment projected to grow at 10.1% CAGR through 2030

The market spans blood glucose monitoring devices, insulin delivery systems, and the fast-growing digital diabetes management niche, which includes CGM systems and smart insulin pumps. The digital diabetes management segment alone is expected to expand at an 8.6% CAGR from 2025 to 2030, outpacing traditional device categories. Within Spain, adoption tends to concentrate in major urban centers and regions with higher healthcare infrastructure investment.

• •Traditional glucose monitoring and insulin pumps remain core segments
• •Digital diabetes management segment growing at 8.6% CAGR through 2030
• •Regional adoption varies with healthcare infrastructure availability

What are the recent trends and outlook?

The market is expected to sustain mid-to-high single-digit annual growth through 2030, supported by ongoing digitization of diabetes care and expanding indications for connected devices. Integration of CGM data with insulin pumps and mobile health platforms is creating more seamless management ecosystems for patients and clinicians. Long-term forecasts vary by methodology, but consensus points to continued expansion as reimbursement frameworks evolve and next-generation devices enter the Spanish market.

• •Market projected to maintain approximately 8-9% annual growth through 2030
• •Integrated CGM-insulin pump ecosystems gaining clinical adoption
• •Next-generation connected devices expected to enter market over forecast horizon